ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,180.74
1.03%
Dow Jones
38,852.27
0.00%
US Dollar vs MXN
16.8649
-0.12%
Brent Oil
83.035
-0.53%
Bitcoin
63,654.78
0.77%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Mirati Therapeutics Inc (MRTX)

  7. Mirati Therapeutics Inc (MRTX) Noticias

MRTX Mirati Therapeutics Inc

58.70
0.00 (0.00%)
Pre Mercado
Última actualización: 19:00:00
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Mirati Therapeutics Inc MRTX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.00 0.00% 58.70 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
58.70
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
14/2/202413:51EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202408:13EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
02/2/202415:05EDGAR2Form 15-12G - Securities registration termination [Section..
24/1/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
23/1/202419:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/1/202419:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/1/202419:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/1/202419:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/1/202419:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/1/202419:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/1/202419:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/1/202408:31EDGAR2Form S-8 POS - Securities to be offered to employees in..
23/1/202408:30EDGAR2Form POSASR - Post-effective Amendment to an automatic shelf..
23/1/202408:28EDGAR2Form POS AM - Post-Effective amendments for registration..
23/1/202408:27EDGAR2Form POS AM - Post-Effective amendments for registration..
23/1/202407:48EDGAR2Form 8-K - Current report
18/1/202415:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/1/202415:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/1/202407:00PRNUSEuropean Commission Approves KRAZATI (adagrasib) as a..
09/1/202416:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202416:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202417:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202417:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202417:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202417:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202417:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202416:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202416:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/12/202315:05EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
19/12/202315:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/12/202306:30EDGAR2Form 8-K - Current report
14/12/202316:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/12/202315:30EDGAR2Form 8-K - Current report
06/12/202307:29EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
01/12/202315:43EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
24/11/202315:45EDGAR2Form 8-K - Current report
15/11/202307:49EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
10/11/202306:30PRNUSMirati Therapeutics Receives Positive Opinion from CHMP for..
06/11/202307:05EDGAR2Form 8-K - Current report
06/11/202307:00PRNUSMirati Therapeutics Reports Third Quarter 2023 Financial..
06/11/202306:08EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/11/202316:19PRNUSMirati Therapeutics Receives Approval from the MHRA for..
02/11/202306:30EDGAR2Form DEFM14A - Definitive proxy statement relating to merger..
02/11/202306:30GLOBEKura Oncology and Mirati Therapeutics Enter into Clinical..
23/10/202316:31EDGAR2Form PREM14A - Preliminary proxy statements relating to..
17/10/202315:00PRNUSMirati Presents Late-Breaking Results Evaluating the..
11/10/202306:31EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
10/10/202306:35EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
10/10/202306:33EDGAR2Form 8-K - Current report
10/10/202306:31EDGAR2Form DEFA14A - Additional definitive proxy soliciting..

Su Consulta Reciente

NASDAQ
MRTX
Mirati Therapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados